CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

NCT00026312

Clinical Trial Information

Trial Number: NCT00026312 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

Study ID:

ANBL0032

Images are available?:

Is this a NCI-MATCH Trial?:

NCT00567567

Clinical Trial Information

Trial Number: NCT00567567 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma

Study ID:

ANBL0532

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00567567-D1	There is one dataset associated with the publication: NCT00567567-D1. USI is the patient identifier and blanks or "." represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning). NCT00567567-D1: There is one row for each patient enrolled on the study ANBL0532. The dataset provides the information necessary to reproduce the manuscript.

Title

Description

NCT00567567-D1

There is one dataset associated with the publication: NCT00567567-D1.
USI is the patient identifier and blanks or "." represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).
NCT00567567-D1: There is one row for each patient enrolled on the study ANBL0532. The dataset provides the information necessary to reproduce the manuscript.

NCT01798004

Clinical Trial Information

Trial Number: NCT01798004 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma

Study ID:

ANBL12P1

Images are available?:

Is this a NCI-MATCH Trial?:

NCT00070200

Clinical Trial Information

Trial Number: NCT00070200 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

A Pilot Induction Regimen Incorporating Topotecan for Treatment of Newly Diagnosed High Risk Neuroblastoma

Study ID:

ANBL02P1

Images are available?:

Is this a NCI-MATCH Trial?:

NCT00004188

Clinical Trial Information

Trial Number: NCT00004188 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma

Study ID:

A3973

Images are available?:

Is this a NCI-MATCH Trial?:

NCT00499616

Clinical Trial Information

Trial Number: NCT00499616 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma

Study ID:

ANBL0531

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00499616-D7	There are two datasets associated with the publication: NCT00499616‐D6 and NCT00499616‐D7. USI is the patient identifier in all datasets. Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning). NCT00499616-D7: There is one row for each adverse event experienced during cycles 1‐8 and retrieval therapy cycles 9‐14. Adverse events that were not graded as moderate, life threatening, or the cause of death were excluded.
NCT00499616-D6	There are two datasets associated with the publication: NCT00499616‐D6 and NCT00499616‐D7. USI is the patient identifier in all datasets. Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning). NCT00499616‐D6: There is one row for each patient enrolled on ANBL0531. The dataset provided provides the information necessary to reproduce the manuscript, except for the toxicities.
NCT00499616-D5	There are five datasets associated with the publication: NCT00499616-D1, NCT00499616-D2, NCT00499616-D3, NCT00499616-D4, NCT00499616-D5. USI is the patient identifier in all datasets. Blanks and '.' represent missing data or not applicable for analyses. For various reasons, data may contain slight discrepancies from that reported in the publication. NCT00499616-D5: Each row represents one intermediate risk stage 4S patient enrolled on ANBL0531. The dataset provided, when used with other datasets submitted under this NCT number, supplies the information necessary to reproduce patient baseline characteristics, survival, and other results of the manuscript.
NCT00499616-D4	There are five datasets associated with the publication: NCT00499616-D1, NCT00499616-D2, NCT00499616-D3, NCT00499616-D4, NCT00499616-D5. USI is the patient identifier in all datasets. Blanks and '.' represent missing data or not applicable for analyses. For various reasons, data may contain slight discrepancies from that reported in the publication. NCT00499616-D4: Each row represents one intermediate risk stage 4S patient enrolled on ANBL0531 and the treatment they received.
NCT00499616-D3	There are five datasets associated with the publication: NCT00499616-D1, NCT00499616-D2, NCT00499616-D3, NCT00499616-D4, NCT00499616-D5. USI is the patient identifier in all datasets. Blanks and '.' represent missing data or not applicable for analyses. For various reasons, data may contain slight discrepancies from that reported in the publication. NCT00499616-D3: Data required for replicating Table 4 in the publication.
NCT00499616-D2	There are five datasets associated with the publication: NCT00499616-D1, NCT00499616-D2, NCT00499616-D3, NCT00499616-D4, NCT00499616-D5. USI is the patient identifier in all datasets. Blanks and '.' represent missing data or not applicable for analyses. For various reasons, data may contain slight discrepancies from that reported in the publication. NCT00499616-D2: Each row represents one baseline abnormality reported on ANBL0531.
NCT00499616-D1	There are five datasets associated with the publication: NCT00499616-D1, NCT00499616-D2, NCT00499616-D3, NCT00499616-D4, NCT00499616-D5. USI is the patient identifier in all datasets. Blanks and '.' represent missing data or not applicable for analyses. For various reasons, data may contain slight discrepancies from that reported in the publication. NCT00499616-D1: There is one row for each stage 4S patient enrolled on ANBL00B1. The dataset provided, when used with other datasets submitted under this NCT number, provides the information necessary to reproduce patient baseline characteristics, survival, and other results of the manuscript.

NCT00033293

Clinical Trial Information

Trial Number: NCT00033293 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

A Pilot Study Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone

Study ID:

ANBL00P3

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00033293-D3	There are three datasets: NCT00033293-D1 NCT00033293-D2 and NCT00033293-D3 for PMID 29376112. USI is the patient identifier in all datasets. NCT00033293-D3 There is one row for each patient used to create Supplemental Table 2 of the manuscript. The dataset provides the information necessary to reproduce the distribution of OMA scores by symptom and time point.
NCT00033293-D2	There are three datasets: NCT00033293-D1 NCT00033293-D2 and NCT00033293-D3 for PMID 29376112. USI is the patient identifier in all datasets. NCT00033293-D2 Each row represents one adverse event used in the manuscript or one row per patient if no adverse event of interest was experienced. These data provide specific incidence of adverse events of interest to recreate Table 3 found in the manuscript.
NCT00033293-D1	There are three datasets: NCT00033293-D1 NCT00033293-D2 and NCT00033293-D3 for PMID 29376112. USI is the patient identifier in all datasets. NCT00033293-D1 There is one row for each patient enrolled on ANBL00P3. The dataset provides the information necessary to reproduce patient baseline characteristics, evaluability, treatment received, disease response, and survival.

NCT01041638

Clinical Trial Information

Trial Number: NCT01041638 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

A Comprehensive Safety Trial of Chimeric Antibody 14.18 (Ch14.18) With GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy

Study ID:

ANBL0931

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT01041638-D4	Each row represents the highest of grade one and two adverse events per patient, per reporting period. This dataset can be used with NCT01041638-D1 to create supplemental table 1.
NCT01041638-D3	There is one row for each patient enrolled on ANBL0931. These data can be used to reproduce pharmacokinetics analysis presented in the manuscript.
NCT01041638-D2	Each row represents one adverse event used in the manuscript. These data provide specific incidence of adverse events of interest.
NCT01041638-D1	The data and analysis for the results reported in Table 6 in the paper published was completed externally. Given the limited access to the original data, Table 6 subsequently has not been able to be replicated. There is one row for each patient enrolled on ANBL0931. The dataset provides the information necessary to reproduce patient baseline characteristics, disease outcome, and survival for patients on ANBL0931.

NCT00716976

Clinical Trial Information

Trial Number: NCT00716976 (ClinicalTrials.gov)

Disease Type:

Bone Neoplasm - Osteosarcoma
CNS Neoplasm (Primary Tumor) - Embryonal Tumors
CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma
Gastrointestinal Neoplasm - Liver and Hepatobiliary Cancer
Germ Cell Neoplasm - Miscellaneous
Miscellaneous Neoplasm - Solid Tumor

Trial Title:

A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children

Study ID:

ACCL0431

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00716976-D3	NCT00716976-D3 One row for each of the 194 serious adverse events detailed on manuscript page 69. These events are reported through the National Cancer Institute, Cancer Therapy Evaluation Program, Adverse Event Reporting System (CTEP-AERS).
NCT00716976-D2	NCT00716976-D2 These data provide the incidence of toxicities. There is one record per patient-cycle. analysiset2=1 for rows included in Table 3 construction. analysiset3=1 for rows included in Table 4 construction.
NCT00716976-D1	NCT00716976-D1 There is one row for each patient enrolled. The first 14 variables are used to make Figure 1. Patients considered for analysis of study outcomes have the variable analysiset1=1. Variables 15-50 provide patient characteristics (Table 1), outcome (Figures 2 and 3) and hearing loss comparisons (Table 2).

Subscribe to CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security

U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov

NIH…Turning Discovery Into Health^®